If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Products to launch on Sephora.co.uk

10 May 2023 07:00

RNS Number : 8579Y
Cellular Goods PLC
10 May 2023
 

Press release

 

10 May 2023

 

 

Cellular Goods PLC

 

('Cellular Goods' or 'the Company')

 

Products to launch on Sephora.co.uk

 

Cellular Goods (LSE: CBX), a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, is pleased to announce that it has entered into a contract with multinational beauty and cosmetics retailer Sephora to make the Company's 'Look Better' (skincare) range available for purchase on Sephora's e-commerce website, Sephora.co.uk from the second half of May.

 

Cellular Goods will become the first cannabigerol (CBG)-based skincare brand to offer its products on Sephora UK, as part of the Company's enhanced retail strategy to drive growth by expanding its sales channels and increasing its collaboration with established online and high street outlets.

 

Sephora.co.uk will stock the full range of the Company's facial skincare products including the brand's best-selling Rejuvenating Face Serum, designed to visibly reverse signs of skin ageing, whilst also protecting from inflammation and irritation. Cellular Goods' newest range of skincare products, the Rejuvenating Night Cream, SPF 25 Rejuvenating Day Cream and Rejuvenating Day Mousse, containing the Company's proprietary formulation of CBG and CBD, will also be available on the website.

 

Additional Cellular Goods products available on Sephora.co.uk include the Company's CBG-based Nourishing Cannabinoid Face Oil, and Calming Cannabinoid After Shaving Moisturiser, as well as selected 'mini' sizes and gifting products during seasonal moments.

 

Darcy Taylor, Chairman and Interim CEO of Cellular Goods, commented: "I'm delighted that our products will be going on sale at Sephora.co.uk. The launch bridges the gap between customer awareness and sales by making it easier for customers to purchase our products. We're confident that our effective next-generation skincare formulations will appeal to their existing customers and encourage them to try our CBG-powered products. The Sephora launch is part of our continued customer acquisition strategy, as we continue to increase awareness of our products and grow our sales channels."

 

For further information please contact:

Cellular Goods

Darcy Taylor

Chairman and interim CEO

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

First Sentinel Corporate Finance

Corporate Broker & Advisor

Brian Stockbridge

 

+44 7876 888 011

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLSSIFAUEDSESI
Date   Source Headline
23rd Dec 20227:00 amRNSTR-1: Standard notification of major holdings
23rd Dec 20227:00 amRNSCellular Goods Annual Results
23rd Nov 20226:16 pmRNSTR-1: Standard notification of major holdings
2nd Nov 202210:34 amRNSTR-1: Standard notification of major holdings
24th Oct 20227:00 amRNSProducts launch on Debenhams.com
20th Oct 20227:00 amRNSLaunch of gift set collection for festive season
26th Sep 20227:00 amRNSProposed purchase of Cannaray Brands and Love CBD
23rd Sep 20225:49 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20225:47 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20225:42 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20227:00 amRNSCellular Goods now shipping products to the USA
23rd Sep 20227:00 amRNSCellular Goods now shipping products to the USA
21st Sep 20222:06 pmRNSSecond Price Monitoring Extn
21st Sep 20222:00 pmRNSPrice Monitoring Extension
21st Sep 20227:00 amRNSLaunch of three new skincare products
6th Sep 20227:00 amRNSPublication of new white paper
17th Aug 20227:00 amRNSGrant of Share Options
16th Aug 20227:00 amRNSAppointment of new Chief Financial Officer
5th Aug 20224:40 pmRNSSecond Price Monitoring Extn
5th Aug 20224:35 pmRNSPrice Monitoring Extension
4th Aug 20229:05 amRNSSecond Price Monitoring Extn
4th Aug 20229:00 amRNSPrice Monitoring Extension
3rd Aug 20224:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
2nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
2nd Aug 202211:05 amRNSSecond Price Monitoring Extn
2nd Aug 202211:00 amRNSPrice Monitoring Extension
1st Aug 20222:00 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSUpdate on marketing initiatives and YouGov survey
11th Jul 20227:00 amRNSLaunch of minis
20th Jun 20227:00 amRNSLaunch of CBG and CBD petition
30th May 20227:00 amRNSInterim results
20th May 20227:00 amRNSTR-1: Standard notification of major holdings
20th May 20227:00 amRNSTR-1: Standard notification of major holdings
16th May 20222:05 pmRNSSecond Price Monitoring Extn
16th May 20222:00 pmRNSPrice Monitoring Extension
12th May 20227:00 amRNSBoard changes
28th Apr 20227:00 amRNSInvestor presentation
28th Apr 20227:00 amRNSFirst patent application filed
22nd Apr 20226:04 pmRNSUpdate on ingestibles product range
22nd Apr 20227:00 amRNSWhite paper on lab-produced cannabinoids
13th Apr 20227:00 amRNSUpdate on ingestibles product range
11th Apr 20227:00 amRNSUpdate on ingestibles products
7th Apr 202210:24 amRNSTR-1: Standard notification of major holdings
1st Apr 20222:05 pmRNSSecond Price Monitoring Extn
1st Apr 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.